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Introduction: Mirtazapine is a noradrenergic and serotonergic anti-
depressant mainly acting through blockade of presynaptic alpha-2 
receptors. Published data on pregnancy outcome after exposure to 
mirtazapine are scarce. This study addresses the risk associated with 
exposure to mirtazapine during pregnancy.
Patients (or Materials) and Methods: Multicenter (n = 11), observa-
tional prospective cohort study comparing pregnancy outcomes after 
exposure to mirtazapine with 2 matched control groups: exposure 
to any selective serotonin reuptake inhibitor (SSRI) as a disease-
matched control group, and general controls with no exposure to 
medication known to be teratogenic or to any antidepressant. Data 
were collected by members of the European Network of Teratology 
Information Services (ENTIS) during individual risk counseling 
between 1995 and 2011. Standardized procedures for data collec-
tion were used in each center.
Results: A total of 357 pregnant women exposed to mirtazapine 
at any time during pregnancy were included in the study and com-
pared with 357 pregnancies from each control group. The rate of 
major birth defects between the mirtazapine and the SSRI group 
did not differ significantly (4.5% vs 4.2%; unadjusted odds ratio, 
1.1; 95% confidence interval, 0.5–2.3, P = 0.9). A trend toward a 
higher rate of birth defects in the mirtazapine group compared with 
general controls did not reach statistical significance (4.2% vs 1.9%; 
OR, 2.4; 95% CI, 0.9–6.3; P = 0.08). The crude rate of spontane-
ous abortions did not differ significantly between the mirtazapine, 
the SSRI, and the general control groups (9.5% vs 10.4% vs 8.4%; 
P = 0.67), neither did the rate of deliveries resulting in live births 
(79.6% vs 84.3% in both control groups; P = 0.15). However, a 
higher rate of elective pregnancy-termination was observed in the 
mirtazapine group compared with SSRI and general controls (7.8% 
vs 3.4% vs 5.6%; P = 0.03). Premature birth (< 37 weeks) (10.6% 
vs 10.1% vs 7.5%; P = 0.38), gestational age at birth (median, 39 
weeks; interquartile range (IQR), 38–40 in all groups; P = 0.29), 
and birth weight (median, 3320 g; IQR, 2979–3636 vs 3230 g; IQR, 
2910–3629 vs 3338 g; IQR, 2967–3650; P = 0.34) did not differ 
significantly between the groups.
Conclusion: This study did not observe a statistically significant 
difference in the rate of major birth defects between mirtazapine, 
SSRI-exposed, and nonexposed pregnancies. A slightly higher rate 
of birth defects was, however, observed in the mirtazapine and SSRI 
groups compared with the low rate of birth defects in our general 
controls. Overall, the pregnancy outcome after mirtazapine exposure 
in this study is very similar to that of the SSRI-exposed control group.
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Introduction: Spontaneous abortions are the most common com-
plication of pregnancy and nonsteroidal anti-inflammatory drugs 
(NSAID) are among the most widely used groups of drugs during the 
first trimester of pregnancy. Published data are inconsistent regarding 
the risk for spontaneous abortions after exposure to NSAID.
Patients (or Materials) and Methods: A population-based retrospec-
tive cohort study was conducted including all women who conceived 
between January 2003 and December 2009 and admitted for birth 
or diagnosed with spontaneous abortion at Soroka Medical Center, 
Clalit Health Services, Israel. A computerized database of medica-
tion dispension was linked with 2 computerized databases contain-
ing information on births and spontaneous abortions. Time-varying 
COX regression models were constructed adjusting for mother’s age, 
diabetes mellitus, hypothyroidism, hypercoagulable or inflammatory 
conditions, history of recurrent miscarriages, presence of intrauterine 
contraceptive device, ethnicity, and self-reporting tobacco use during 
pregnancy and the year of pregnancy.
Results: There were 65,457 women who conceived during the study 
period and admitted at SMC: 58,949 (90.1%) for birth and 6508 
(9.9%) for spontaneous abortion. A total of 4495 (6.9%) pregnant 
women were exposed to NSAID during the study period. Exposure 
to NSAID was not an independent risk factor for spontaneous abor-
tion as groups (adjusted hazard ratio [HR], 1.08; 95% confidence 
interval [CI], 0.97–1.20 and adjusted HR, 1.67; 95% CI 0.95–2.95 
for nonselective and selective COX2 inhibitors, respectively) or as 
specific drugs. Additionally, no dose response effect was found.
Conclusion: In this large population-based retrospective cohort 
study, no increased risk for spontaneous abortions was found fol-
lowing exposure to NSAID Table. 
Table.  The unadjusted and adjusted risk (hazard ratios and 
95% CI) for spontaneous abortion following exposure 
to NSAID: results from time-varying multivariate Cox 
regression models.
Spontaneous abortions  
Hazard ratio (95% Ci)
unadjusted adjusted*
Nonselective COX inhibitors 1.13 (1.01–1.25) 1.08 (0.97–1.20)
Ibuprofen 1.13 (0.98–1.30) 1.05 (0.92–1.21)
Diclofenac 1.21 (0.98–1.48) 1.19 (0.97–1.47)
Indomethacin 3.54 (2.20–5.71) 3.33 (2.06–5.36)
Naproxen 1.87 (0.66–1.17) 0.88 (0.66–1.18)
Etodolac 1.26 (0.88 –1.80) 0.14 (0.8–1.64)
COX2 selective inhibitors 1.97 (1.12–3.47) 1.67 (0.95–2.95)
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Introduction: The pharmaceutical aspects of drug administration in 
clinical trials receive poor consideration compared with the impor-
tant attention devoted to the analytical and mathematical aspects 
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of biological sample exploitation. During PK calculations, many 
researchers merely use for dose the nominal amount declared, over-
looking the noticeable biases that may result in the assessment of PK 
parameters. The aim of this work was to evaluate the biases related 
to doses injected of a biosimilar drug in 2 Phase I clinical trials.
Patients (or Materials) and Methods: In trial A, 12 healthy volun-
teers received different doses of a biosimilar of interferon beta-1a by 
either subcutaneous (SC) or intravenous (IV) injection. The doses 
were prepared by partially emptying 0.5-mL syringes supplied by 
the manufacturer (drop count procedure). In trial B, 12 healthy vol-
unteers received 3 different formulations of the drug by IV injection 
(biosimilar without albumin [HSA], biosimilar with HSA and original 
brand [Rebif®]) and 2 different formulations as multiple SC injec-
tions (biosimilar HSA-free and original brand). In both trials, the 
actual dose administered was calculated as: D = C·V – losses. The 
product titer C was assessed by ELISA. The volume administered IV 
was assessed by weighting. Losses were evaluated by in vitro experi-
ments. Finally, the binding of 125I-interferon to HSA was evaluated 
by counting the free and HSA complexed molecule fractions sepa-
rated by gel filtration.
Results: Interferon was not significantly adsorbed onto the lines used 
for its IV administration. In trial A, the titer was very close to the one 
declared (96 ± 7%). In trial B, it differed significantly (156 ± 10% 
for biosimilar with/without HSA and 123 ± 5% for original for-
mulation). In trial A, the dose actually administered showed a large 
variability. The real injected volume could be biased up to 75% com-
pared with the theoretical volume (for the lower dose administered 
[ie, 0.03 mL]). This was mainly attributed to a partial re-aspiration 
of the drug solution before withdrawing the syringe needle. A strict 
procedure was therefore applied in trial B to avoid these inaccuracies. 
Finally, in trial B, 125I-Interferon beta-1a binding to HSA appeared 
time dependent and slow, reaching 50% after 16-hour incubation, 
which is close to steady state reported for the comparator Rebif®.
Conclusion: These practical examples (especially biases on actual 
titer and volume injected) illustrate that actual dose assessment 
deserves attention to ensure accuracy for estimates of clearance and 
distribution volume in the scientific literature and for registration 
purposes, especially for bioequivalence studies.
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Introduction: Increasing efforts have been made on the research 
of new predictive biomarkers in drug development, particularly in 
oncology. In this context, the validation process represents a difficult 
task with some potential methodologic limitations. In the present 
study, we will perform a critical review of the validation process of 
6 key biomarkers in oncology.
Patients (or Materials) and Methods: Six biomarkers were selected 
considering their relevance in drug development over the last dec-
ade in oncology: HER-2, EGFR, KRAS, C-KIT ALK, and C-Met. 
A review of literature was performed in PubMed, Cochrane, and 
EMBASE, and in regulatory agencies public websites. A critical 
review of available data in relation to regulatory requirements (EMA 
and FDA) has been conducted considering the following elements: 
at which stage of drug development the biomarker was considered 
in defining the target population; type of clinical data used for the 
biomarker validation process; impact of the biomarker in the final 
labeling; and availability of a standardized test applicable in clinical 
practice.
Results: Results are displayed according to recommendations of 
regulatory agencies on the necessary procedural steps for the valida-
tion process preapproval.
Conclusion: Data analyzed allow to distinguish 2 different scenarios. 
Those situations in which the biomarker development was the con-
sequence of a primarily failing drug development strategy (EGFR 
and KRAS) and those in which the biomarker was a key element 
prospectively considered in drug development (ALK, HER2, C-KIT 
and C-met). Regulatory decisions were adopted sometimes based on 
purely retrospective strategies. The authors will critically describe 
such circumstances and the potential clinical implications of such 
decisions.
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Introduction: An integrated final exam for medical students was 
introduced at Karolinska Institutet, Stockholm, Sweden, in 2012. 
The exam is scenario based and consists of six 20-minute stations, 
1 of which has been designed to assess clinical pharmacology (CP) 
skills. The overall aim of the exam is to assess the knowledge (both 
Triggering  
Facts
labeling  
implications
Standarized  
Test
HER-2 Biomarker-based 
drug development
Restricted labeling to 
HER2 overexpression or 
HER2 gene amplification
+
EGFR Failed studies in 
NSCLC
Unrestricted labeling 
in US
−
Negative opinion in EU −
EGFR+ patients 
at a later stage 
once prospectively 
validated
KRAS Failed studies in 
mCRC
KRASwt in EU
Negative opinion in US
KRASwt at a later stage 
in US and EU once 
prospectively confirmed
+
C-KIT Exploratory 
analyses through 
the different 
indications
Not reflected in labeling −
ALK Biomarker-based 
drug development
Restricted labeling to 
anaplastic lymphoma 
kinase (ALK)-positive in 
NSCLC
+
C-Met Biomarker-based 
drug development
Not reflected yet −
